

\*\*\*

**Proposed Proclamation**  
**for**  
**Prostate Cancer Awareness Month**  
**September 2018**



## **Proposed Proclamation**

### **Prostate Cancer Awareness Month – September 2018**

#### **Table of Contents**

| <b>Page</b> | <b>Subject</b>  |
|-------------|---|
| 1.          | Table of Contents   |
| 2.          | Discussion  |
| 3.          | Proposed Proclamation   |
| 4.          | Reference: ACS Cancer Facts & Figures 2018                        |
| 5.          | Reference: ACS Cancer Facts & Figures 2018                        |
| 6.          | Reference: ACS Cancer Facts & Figures 2018                        |
| 7.          | Reference: ACS Cancer Facts & Figures 2018                        |
| 8.          | Reference: ACS Cancer Facts & Figures 2018                        |
| 9.          | White House Prostate Cancer Awareness Statement                   |
| 10.         | U.S. Senate Prostate Cancer Awareness Resolution (2 pages)        |
| 11.         | California Senate & Assembly Prostate Cancer Awareness Resolution |

The American Cancer Society document Cancer Facts & Figures 2018 is the source document for all of the information in this Proposed Proclamation. It can be found on the ACS website: [www.cancer.org](http://www.cancer.org). In the Search box, type Cancer Facts Figures. The entire 76-page document is available in a PDF format.

#### **Prepared by**

Bill Doss  
California Prostate Cancer Coalition  
4909 Moonshadow Court  
Rocklin, CA 95677  
916-772-2222  
[wdoss@surewest.net](mailto:wdoss@surewest.net)  
[www.prostatecalif.org](http://www.prostatecalif.org)

## **Proposed Proclamation**

### **Prostate Cancer Awareness Month – September 2018**

#### **Discussion**

The purpose of this report is to assist government agencies issue a Proclamation designating September 2018 as Prostate Cancer Awareness Month. In this report, the word “Resolution” may be substituted for the word “Proclamation” as required by the issuing government body. The proposed Proclamation on page 3 is in keeping with the national historical practice of recognizing September as Prostate Cancer Awareness Month.

The proposed Proclamation on the next page was prepared using the references listed in this report. All of the references in this report are from American Cancer Society 2018 sources. There is a page number in parenthesis after each WHEREAS. This page number refers to the location in this report for the source of the WHEREAS. Information on each reference page has been underlined to assist the reader identify the source for each WHEREAS.

There are more than 2.9 million men alive in the USA with a history of prostate cancer. Prostate cancer is the most diagnosed cancer in men today, second only to skin cancer. The American Cancer Society estimates that 1 in 9 men will develop prostate cancer in their lifetime. Prostate cancer is the second leading cause of cancer deaths in men after lung cancer. Every 18 minutes, 24/7, an American man dies from prostate cancer.

More men are diagnosed with prostate cancer in California than any other state. California also has the highest number of deaths from this disease. It is estimated that this year in the state, 15,190 men will be diagnosed and 3,490 men will die from this disease.

The early stages of prostate cancer usually show no symptoms and there are no self-tests for this disease. Early detection is the key to prostate cancer survival. The 5-year survival rate for prostate cancer approaches 100% if the disease is treated early. The 5-year survival rate drops to 30% if the cancer has metastasized. Treatment options for prostate cancer vary depending on a man’s age, the cancer stage and grade, as well as the patient’s other medical conditions. The patient’s personal values and preferences are also a consideration.

Each year, the President of the United States, The United States Senate, and the Governors of many States issue Proclamations declaring September as Prostate Cancer Awareness Month. Many counties and cities across the country also recognize Prostate Cancer Awareness Month in September by issuing their own Proclamations.

Copies of last year’s Prostate Cancer Awareness Proclamations from the White House, US Senate, and California Senate and Assembly, are provided at the end of this report for the reader to review the format and phrasing used in other Proclamations.

---

## **Proposed Proclamation**

### **Prostate Cancer Awareness Month – September 2018**

This is a Proclamation to designate September 2018 as Prostate Cancer Awareness Month.

1 WHEREAS, prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer deaths in men; and (page 4)

2 WHEREAS, the American Cancer Society estimates there will be 164,690 new cases of prostate cancer in the USA in 2018, resulting in an estimated 29,430 deaths; and (pages 5 & 6)

3 WHEREAS, it is estimated 15,190 men in California will be diagnosed with prostate cancer this year and it is estimated 3,490 California men will die from this disease; and (pages 7 & 8)

4 WHEREAS, Black men in the USA and Caribbean have the highest documented prostate cancer incidence rates in the world; and (page 6)

5 WHEREAS, early prostate cancer usually has no symptoms and studies suggest strong familial predisposition may be responsible for 5% to 10% of the disease cases; and (page 6)

6 WHEREAS, advanced prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas in the body; and (page 6)

7 WHEREAS, the 5-year survival rate approaches 100% when prostate cancer is diagnosed and treated early, but drops to 30% when it spreads to the other parts of the body; and (page 5)


8 WHEREAS, the American Cancer Society recommends that men should have an opportunity to make an informed decision about whether to be tested for prostate cancer based on their personal values and preferences; and (page 6)

9 WHEREAS, prostate cancer treatment decisions should be based on clinician recommendations and patient values and preferences; and (page 6)


10 WHEREAS, the (name of issuing governing body) joins communities across our nation to increase the awareness about the importance for men to make an informed decision with their health care provider about early detection and testing for prostate cancer, and now, therefore be it

11 RESOLVED, that the (name of issuing government body) designate September 2018 as Prostate Cancer Awareness Month.

**Figure 3. Leading Sites of New Cancer Cases and Deaths – 2018 Estimates**

|                     | Male                           |                |             |   | Female                |                |             |
|---------------------|--------------------------------|----------------|-------------|---|-----------------------|----------------|-------------|
| Estimated New Cases | Prostate                       | 164,690        | 19%         |  | Breast                | 266,120        | 30%         |
|                     | Lung & bronchus                | 121,680        | 14%         |   | Lung & bronchus       | 112,350        | 13%         |
|                     | Colon & rectum                 | 75,610         | 9%          |   | Colon & rectum        | 64,640         | 7%          |
|                     | Urinary bladder                | 62,380         | 7%          |   | Uterine corpus        | 63,230         | 7%          |
|                     | Melanoma of the skin           | 55,150         | 6%          |   | Thyroid               | 40,900         | 5%          |
|                     | Kidney & renal pelvis          | 42,680         | 5%          |   | Melanoma of the skin  | 36,120         | 4%          |
|                     | Non-Hodgkin lymphoma           | 41,730         | 5%          |   | Non-Hodgkin lymphoma  | 32,950         | 4%          |
|                     | Oral cavity & pharynx          | 37,160         | 4%          |   | Pancreas              | 26,240         | 3%          |
|                     | Leukemia                       | 35,030         | 4%          |   | Leukemia              | 25,270         | 3%          |
|                     | Liver & intrahepatic bile duct | 30,610         | 4%          |   | Kidney & renal pelvis | 22,660         | 3%          |
|                     | <b>All sites</b>               | <b>856,370</b> | <b>100%</b> |   | <b>All sites</b>      | <b>878,980</b> | <b>100%</b> |

|                  | Male                           |                |             |   | Female                         |                |             |
|------------------|--------------------------------|----------------|-------------|---|--------------------------------|----------------|-------------|
| Estimated Deaths | Lung & bronchus                | 83,550         | 26%         |  | Lung & bronchus                | 70,500         | 25%         |
|                  | Prostate                       | 29,430         | 9%          |   | Breast                         | 40,920         | 14%         |
|                  | Colon & rectum                 | 27,390         | 8%          |   | Colon & rectum                 | 23,240         | 8%          |
|                  | Pancreas                       | 23,020         | 7%          |   | Pancreas                       | 21,310         | 7%          |
|                  | Liver & intrahepatic bile duct | 20,540         | 6%          |   | Ovary                          | 14,070         | 5%          |
|                  | Leukemia                       | 14,270         | 4%          |   | Uterine corpus                 | 11,350         | 4%          |
|                  | Esophagus                      | 12,850         | 4%          |   | Leukemia                       | 10,100         | 4%          |
|                  | Urinary bladder                | 12,520         | 4%          |   | Liver & intrahepatic bile duct | 9,660          | 3%          |
|                  | Non-Hodgkin lymphoma           | 11,510         | 4%          |   | Non-Hodgkin lymphoma           | 8,400          | 3%          |
|                  | Kidney & renal pelvis          | 10,010         | 3%          |   | Brain & other nervous system   | 7,340          | 3%          |
|                  | <b>All sites</b>               | <b>323,630</b> | <b>100%</b> |   | <b>All sites</b>               | <b>286,010</b> | <b>100%</b> |

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Ranking is based on modeled projections and may differ from the most recent observed data.

©2018, American Cancer Society, Inc., Surveillance Research

## Breast

**New cases:** In the US in 2018, there will be an estimated 266,120 new cases of invasive breast cancer diagnosed in women (Figure 3); 2,550 cases diagnosed in men; and an additional 63,960 cases of in situ breast lesions diagnosed in women (Table 1, page 4).

**Incidence trends:** From 2005 to 2014, the most recent 10 years for which data are available, invasive breast cancer incidence rates were stable in white women and increased slightly (by 0.3% per year) in black women.

**Deaths:** An estimated 41,400 breast cancer deaths (40,920 women, 480 men) will occur in 2018.

**Mortality trends:** The female breast cancer death rate peaked at 33.2 (per 100,000) in 1989, then declined by 39% to 20.3 in 2015. This progress, which is attributed to improvements in early detection (through screening, as well as increased awareness) and treatment, translates to an estimated 322,600 fewer breast cancer deaths than

would have been expected if the death rate had remained at its peak. The annual percent decline from 2006 to 2015 was slightly larger for white women (1.8%) than for black women (1.5%).

**Signs and symptoms:** The most common sign is a lump or mass in the breast. Other symptoms include persistent changes to the breast, such as thickening, swelling, distortion, tenderness, skin irritation, redness, scaliness, and nipple abnormalities or spontaneous nipple discharge. Early breast cancer usually has no symptoms and is most often diagnosed through mammography screening.

**Risk factors:** Like most cancers, older age is the strongest risk factor for breast cancer. Many other factors that influence risk modify exposure of breast tissue to reproductive hormones. Some of these are potentially modifiable, such as weight gain after the age of 18 and/or being overweight or obese (for postmenopausal breast cancer), postmenopausal hormone use (combined estrogen and progestin), physical inactivity, and alcohol consumption; breastfeeding for at least one year

**Table 8. Five-year Relative Survival Rates\* (%) by Stage at Diagnosis, US, 2007-2013**

|                      | All stages | Local | Regional | Distant |                       | All stages | Local | Regional | Distant |
|----------------------|------------|-------|----------|---------|-----------------------|------------|-------|----------|---------|
| Breast (female)      | 90         | 99    | 85       | 27      | Oral cavity & pharynx | 65         | 84    | 64       | 39      |
| Colon & rectum       | 65         | 90    | 71       | 14      | Ovary                 | 47         | 93    | 73       | 29      |
| Colon                | 64         | 91    | 72       | 14      | Pancreas              | 8          | 32    | 12       | 3       |
| Rectum               | 67         | 88    | 70       | 15      | Prostate              | 99         | >99   | >99      | 30      |
| Esophagus            | 19         | 43    | 23       | 5       | Stomach               | 31         | 67    | 31       | 5       |
| Kidney†              | 74         | 93    | 67       | 12      | Testis                | 95         | 99    | 96       | 73      |
| Larynx               | 61         | 77    | 45       | 34      | Thyroid               | 98         | >99   | 98       | 56      |
| Liver‡               | 18         | 31    | 11       | 3       | Urinary bladder§      | 77         | 70    | 35       | 5       |
| Lung & bronchus      | 18         | 56    | 29       | 5       | Uterine cervix        | 67         | 92    | 57       | 17      |
| Melanoma of the skin | 92         | 99    | 63       | 20      | Uterine corpus        | 81         | 95    | 69       | 16      |

\*Rates are adjusted for normal life expectancy and are based on cases diagnosed in the SEER 18 areas from 2007-2013, all followed through 2014. †Includes renal pelvis. ‡Includes intrahepatic bile duct. §Rate for in situ cases is 96%.

**Local:** an invasive malignant cancer confined entirely to the organ of origin. **Regional:** a malignant cancer that 1) has extended beyond the limits of the organ of origin directly into surrounding organs or tissues; 2) involves regional lymph nodes; or 3) has both regional extension and involvement of regional lymph nodes. **Distant:** a malignant cancer that has spread to parts of the body remote from the primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via the lymphatic system to distant lymph nodes.

**Source:** Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute, Bethesda, MD, [http://seer.cancer.gov/csr/1975\\_2014/](http://seer.cancer.gov/csr/1975_2014/), based on November 2016 SEER data submission, posted to the SEER website April 2017.

©2018 American Cancer Society, Inc., Surveillance Research

**Deaths:** An estimated 44,330 deaths from pancreatic cancer will occur in 2018.

**Mortality trends:** From 2006 to 2015, the death rate for pancreatic cancer increased slightly in whites (by 0.2% per year), but decreased in blacks by 0.5% per year.

**Signs and symptoms:** Symptoms for pancreatic cancer, which usually do not appear until the disease has progressed, include weight loss, abdominal discomfort that may radiate to the back, and occasionally the development of diabetes. Tumors sometimes cause jaundice (yellowing of the skin and eyes), which can facilitate earlier diagnosis. Signs of advanced-stage disease may include severe abdominal pain, nausea, and vomiting.

**Risk factors:** The risk of pancreatic cancer in cigarette smokers is about twice that in never smokers. Use of smokeless tobacco also increases risk. Other risk factors include a family history of pancreatic cancer, a personal history of chronic pancreatitis or diabetes, and obesity. Heavy alcohol consumption may increase risk. Individuals with Lynch syndrome and certain other genetic syndromes, as well as *BRCA1* and *BRCA2* mutation carriers, are also at increased risk.

**Treatment:** Surgery, radiation therapy, and chemotherapy are treatment options that may extend

survival and/or relieve symptoms, but seldom produce a cure. Less than 20% of patients are candidates for surgery because pancreatic cancer is usually detected after it has spread beyond the pancreas. For those who undergo surgery, adjuvant treatment with chemotherapy (and sometimes radiation) may lower the risk of recurrence. For advanced disease, chemotherapy (sometimes along with a targeted therapy drug) may lengthen survival. Clinical trials are testing several new targeted agents and immunotherapies.

**Survival:** For all stages combined, the 5-year relative survival rate is 8%. Even for the small percentage of people diagnosed with local disease (10%), the 5-year survival is only 32%. About half (52%) of patients are diagnosed at a distant stage, for which 5-year survival is 3%.

## Prostate

**New cases:** An estimated 164,690 new cases of prostate cancer will be diagnosed in the US during 2018. The risk of prostate cancer is 74% higher in blacks than in whites for reasons that remain unclear.

**Incidence trends:** In the late 1980s and early 1990s, incidence rates for prostate cancer spiked dramatically, in large part because of widespread screening with the prostate-specific antigen (PSA) blood test. The decline in

rates since around 2000 has accelerated in recent years, likely due to recommendations against routine PSA screening beginning in 2008. From 2010 to 2014, the rate decreased by about 10% per year.

**Deaths:** An estimated 29,430 deaths from prostate cancer will occur in 2018.

**Mortality trends:** Prostate cancer death rates have been decreasing since the early 1990s, although rates appear to have stabilized from 2013 to 2015.

**Signs and symptoms:** Early-stage prostate cancer usually has no symptoms; men with more advanced disease may experience weak or interrupted urine flow; difficulty starting or stopping urine flow; the need to urinate frequently, especially at night; blood in the urine; or pain or burning with urination. Advanced prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas.

**Risk factors:** The only well-established risk factors for prostate cancer are increasing age, African ancestry, a family history of the disease, and certain inherited genetic conditions. Black men in the US and Caribbean have the highest documented prostate cancer incidence rates in the world. Genetic studies suggest that strong familial predisposition may be responsible for 5%-10% of prostate cancers. Inherited conditions associated with increased risk include Lynch syndrome and *BRCA1* and *BRCA2* mutations. Smoking may increase the risk of fatal prostate cancer.

**Early detection:** No organizations presently endorse routine prostate cancer screening for men at average risk because of concerns about the high rate of overdiagnosis (detecting disease that would never have caused symptoms), along with the significant potential for serious side effects associated with prostate cancer treatment. The American Cancer Society recommends that beginning at age 50, men who are at average risk of prostate cancer and have a life expectancy of at least 10 years have a conversation with their health care provider about the benefits and limitations of PSA testing and make an informed decision about whether to be tested

based on their personal values and preferences. Men at high risk of developing prostate cancer (black men or those with a close relative diagnosed with prostate cancer before the age of 65) should have this discussion beginning at age 45, and men at even higher risk (those with several close relatives diagnosed at an early age) should have this discussion beginning at age 40.

**Treatment:** Treatment decisions should be based on clinician recommendations and patient values and preferences. Recent changes in the grading system for prostate cancer have improved tumor characterization and disease management. Careful monitoring of disease progression (called active surveillance) instead of immediate treatment is appropriate for many patients, particularly men who are diagnosed at an early stage or have less aggressive tumors or are older. Treatment options include surgery, external beam radiation, or radioactive seed implants (brachytherapy). Hormonal therapy may be used along with surgery or radiation in more advanced cases. Treatment often impacts a man's quality of life due to side effects or complications, such as urinary and erectile difficulties, which may be temporary or long term. Current research is exploring new biologic markers for prostate cancer to minimize unnecessary treatment by improving the distinction between indolent and aggressive disease.

Prostate cancer that has spread to distant sites is treated with hormonal therapy, chemotherapy, radiation therapy, and/or other treatments. Hormone treatment may control advanced prostate cancer for long periods of time by shrinking the size or limiting the growth of the cancer, thus helping to relieve pain and other symptoms. Chemotherapy may be given along with hormone therapy, or it may be used if hormone treatments are no longer effective. An option for some men with advanced prostate cancer that is no longer responding to hormones is a cancer vaccine designed to stimulate the patient's immune system to attack prostate cancer cells specifically. Newer forms of hormone therapy have been shown to be beneficial for treating advanced disease. Other types of drugs can be used to treat prostate cancer that has spread to the bones.

**Table 2. Estimated Number\* of New Cases for Selected Cancers by State, US, 2018**

| State                | All sites        | Female breast  | Uterine cervix | Colon & rectum | Uterine corpus | Leukemia      | Lung & bronchus | Melanoma of the skin | Non-Hodgkin lymphoma | Prostate       | Urinary bladder |
|----------------------|------------------|----------------|----------------|----------------|----------------|---------------|-----------------|----------------------|----------------------|----------------|-----------------|
| Alabama              | 27,830           | 3,760          | 220            | 2,230          | 770            | 830           | 4,190           | 1,380                | 990                  | 2,460          | 1,110           |
| Alaska               | 3,550            | 510            | †              | 270            | 120            | 110           | 460             | 130                  | 140                  | 360            | 160             |
| Arizona              | 34,740           | 5,700          | 270            | 2,840          | 1,210          | 1,150         | 4,460           | 1,880                | 1,480                | 3,180          | 1,810           |
| Arkansas             | 16,130           | 2,160          | 150            | 1,370          | 480            | 510           | 2,720           | 670                  | 650                  | 1,260          | 720             |
| California           | 178,130          | 29,360         | 1,540          | 14,400         | 6,610          | 6,220         | 18,760          | 9,830                | 8,190                | 15,190         | 7,800           |
| Colorado             | 25,570           | 3,630          | 180            | 1,850          | 870            | 910           | 2,560           | 1,640                | 1,100                | 3,190          | 1,180           |
| Connecticut          | 21,240           | 3,540          | 120            | 1,520          | 890            | 760           | 2,700           | 970                  | 970                  | 2,220          | 1,210           |
| Delaware             | 6,110            | 780            | †              | 450            | 210            | 180           | 890             | 380                  | 250                  | 640            | 290             |
| Dist. of Columbia    | 3,260            | 520            | †              | 240            | 120            | 70            | 310             | 120                  | 120                  | 420            | 80              |
| Florida              | 135,170          | 19,860         | 1,100          | 11,670         | 4,450          | 4,770         | 18,710          | 7,940                | 5,990                | 13,630         | 6,600           |
| Georgia              | 56,920           | 7,490          | 430            | 4,120          | 1,600          | 1,590         | 7,160           | 3,040                | 1,970                | 5,340          | 1,960           |
| Hawaii               | 6,280            | 1,150          | 50             | 650            | 280            | 200           | 830             | 490                  | 270                  | 510            | 260             |
| Idaho                | 8,450            | 1,070          | 50             | 630            | 290            | 310           | 1,060           | 590                  | 390                  | 900            | 490             |
| Illinois             | 66,330           | 9,960          | 570            | 5,340          | 2,800          | 2,170         | 9,220           | 2,980                | 2,830                | 6,300          | 3,190           |
| Indiana              | 37,250           | 5,630          | 290            | 3,190          | 1,400          | 1,210         | 5,840           | 1,900                | 1,600                | 3,460          | 1,740           |
| Iowa                 | 17,630           | 2,560          | 110            | 1,510          | 710            | 700           | 2,480           | 1,050                | 810                  | 1,580          | 880             |
| Kansas               | 15,400           | 2,290          | 110            | 1,220          | 530            | 590           | 2,050           | 850                  | 640                  | 1,360          | 660             |
| Kentucky             | 25,990           | 3,720          | 210            | 2,370          | 850            | 960           | 5,150           | 1,440                | 1,060                | 2,210          | 1,200           |
| Louisiana            | 25,080           | 3,570          | 210            | 2,310          | 670            | 740           | 3,660           | 1,000                | 1,040                | 2,600          | 1,000           |
| Maine                | 8,600            | 1,350          | 50             | 660            | 380            | 320           | 1,450           | 470                  | 400                  | 710            | 580             |
| Maryland             | 33,810           | 5,940          | 220            | 2,950          | 1,270          | 910           | 4,270           | 1,690                | 1,290                | 3,470          | 1,500           |
| Massachusetts        | 37,130           | 6,490          | 210            | 2,630          | 1,590          | 1,150         | 5,140           | 2,090                | 1,650                | 4,060          | 2,040           |
| Michigan             | 56,590           | 8,730          | 370            | 4,510          | 2,330          | 1,820         | 8,780           | 2,890                | 2,590                | 5,400          | 3,070           |
| Minnesota            | 31,270           | 4,500          | 140            | 2,270          | 1,120          | 1,270         | 3,980           | 1,420                | 1,420                | 2,920          | 1,380           |
| Mississippi          | 18,130           | 2,240          | 150            | 1,550          | 430            | 560           | 2,690           | 590                  | 560                  | 1,370          | 620             |
| Missouri             | 35,520           | 5,160          | 250            | 2,890          | 1,240          | 1,240         | 5,750           | 1,800                | 1,480                | 3,000          | 1,640           |
| Montana              | 6,080            | 1,020          | †              | 520            | 220            | 230           | 830             | 440                  | 280                  | 810            | 350             |
| Nebraska             | 10,320           | 1,560          | 70             | 900            | 380            | 410           | 1,310           | 540                  | 460                  | 960            | 490             |
| Nevada               | 14,060           | 2,180          | 130            | 1,130          | 410            | 500           | 2,090           | 790                  | 580                  | 1,190          | 770             |
| New Hampshire        | 8,080            | 1,360          | †              | 590            | 360            | 280           | 1,230           | 460                  | 370                  | 840            | 520             |
| New Jersey           | 53,260           | 8,550          | 380            | 4,100          | 2,180          | 1,990         | 5,870           | 2,830                | 2,370                | 5,430          | 2,590           |
| New Mexico           | 9,730            | 1,470          | 80             | 800            | 340            | 360           | 1,090           | 500                  | 410                  | 960            | 390             |
| New York             | 110,800          | 17,890         | 870            | 9,080          | 4,580          | 4,410         | 13,190          | 4,920                | 4,890                | 9,880          | 5,440           |
| North Carolina       | 55,130           | 7,760          | 410            | 4,440          | 1,910          | 2,050         | 8,490           | 3,310                | 2,240                | 5,580          | 2,530           |
| North Dakota         | 4,110            | 570            | †              | 350            | 140            | 150           | 500             | 220                  | 170                  | 380            | 200             |
| Ohio                 | 68,470           | 10,610         | 480            | 5,550          | 2,740          | 2,060         | 10,760          | 3,400                | 2,880                | 5,810          | 3,350           |
| Oklahoma             | 19,030           | 2,870          | 170            | 1,670          | 590            | 710           | 3,210           | 860                  | 860                  | 1,670          | 890             |
| Oregon               | 21,520           | 3,400          | 140            | 1,510          | 890            | 650           | 3,140           | 1,570                | 1,010                | 2,040          | 1,130           |
| Pennsylvania         | 80,960           | 12,140         | 500            | 6,440          | 3,320          | 2,930         | 10,470          | 4,320                | 3,430                | 7,360          | 4,240           |
| Rhode Island         | 5,920            | 1,010          | †              | 460            | 260            | 190           | 880             | 280                  | 270                  | 740            | 360             |
| South Carolina       | 30,450           | 4,540          | 220            | 2,410          | 920            | 960           | 4,630           | 1,820                | 1,150                | 3,080          | 1,310           |
| South Dakota         | 5,100            | 740            | †              | 440            | 170            | 190           | 650             | 270                  | 220                  | 510            | 260             |
| Tennessee            | 36,760           | 5,590          | 310            | 3,110          | 1,130          | 1,370         | 6,030           | 1,900                | 1,540                | 2,750          | 1,660           |
| Texas                | 121,860          | 18,260         | 1,360          | 10,080         | 4,000          | 4,580         | 15,460          | 4,440                | 5,460                | 12,600         | 4,530           |
| Utah                 | 10,950           | 1,720          | 70             | 780            | 400            | 480           | 900             | 1,010                | 520                  | 1,250          | 440             |
| Vermont              | 3,840            | 600            | †              | 270            | 160            | 120           | 560             | 230                  | 170                  | 390            | 250             |
| Virginia             | 42,420           | 7,510          | 290            | 3,380          | 1,570          | 1,250         | 5,860           | 2,620                | 1,760                | 4,200          | 1,900           |
| Washington           | 36,170           | 5,580          | 240            | 2,710          | 1,390          | 1,330         | 4,810           | 2,650                | 1,770                | 3,730          | 1,940           |
| West Virginia        | 12,110           | 1,700          | 90             | 1,030          | 450            | 390           | 2,060           | 720                  | 480                  | 820            | 620             |
| Wisconsin            | 33,340           | 5,420          | 190            | 2,650          | 1,410          | 1,350         | 4,400           | 1,740                | 1,410                | 3,660          | 1,710           |
| Wyoming              | 2,780            | 450            | †              | 210            | 100            | 100           | 330             | 200                  | 120                  | 330            | 160             |
| <b>United States</b> | <b>1,735,350</b> | <b>266,120</b> | <b>13,240</b>  | <b>140,250</b> | <b>63,230</b>  | <b>60,300</b> | <b>234,030</b>  | <b>91,270</b>        | <b>74,680</b>        | <b>164,690</b> | <b>81,190</b>   |

\*Rounded to the nearest 10. Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. †Estimate is fewer than 50 cases. These estimates are offered as a rough guide and should be interpreted with caution. State estimates may not sum to US total due to rounding and exclusion of state estimates fewer than 50 cases.

**Please note:** Estimated cases for additional cancer sites by state can be found in Supplemental Data at [cancer.org/statistics](http://cancer.org/statistics) or via the Cancer Statistics Center at [cancerstatisticscenter.cancer.org](http://cancerstatisticscenter.cancer.org).

©2018, American Cancer Society, Inc., Surveillance Research



**Table 3. Estimated Number\* of Deaths for Selected Cancers by State, US, 2018**

| State                | All sites      | Brain/<br>nervous<br>system | Female<br>breast | Colon &<br>rectum | Leukemia      | Liver†        | Lung &<br>bronchus | Non-<br>Hodgkin<br>lymphoma | Ovary         | Pancreas      | Prostate      |
|----------------------|----------------|-----------------------------|------------------|-------------------|---------------|---------------|--------------------|-----------------------------|---------------|---------------|---------------|
| Alabama              | 10,720         | 330                         | 670              | 950               | 400           | 500           | 3,140              | 300                         | 240           | 740           | 490           |
| Alaska               | 1,120          | †                           | 70               | 100               | †             | 60            | 290                | †                           | †             | 80            | 50            |
| Arizona              | 12,390         | 380                         | 850              | 1,040             | 540           | 680           | 2,850              | 410                         | 310           | 970           | 680           |
| Arkansas             | 6,910          | 190                         | 410              | 600               | 260           | 290           | 2,130              | 200                         | 150           | 430           | 280           |
| California           | 60,650         | 1,860                       | 4,500            | 5,300             | 2,580         | 3,900         | 11,830             | 2,140                       | 1,570         | 4,570         | 3,490         |
| Colorado             | 8,000          | 270                         | 580              | 660               | 340           | 410           | 1,600              | 250                         | 230           | 580           | 510           |
| Connecticut          | 6,590          | 200                         | 410              | 460               | 290           | 320           | 1,570              | 220                         | 160           | 520           | 320           |
| Delaware             | 2,080          | 50                          | 140              | 140               | 80            | 110           | 580                | 70                          | 50            | 160           | 90            |
| Dist. of Columbia    | 1,030          | †                           | 110              | 90                | †             | 80            | 200                | †                           | †             | 90            | 70            |
| Florida              | 45,030         | 1,290                       | 2,940            | 3,640             | 1,820         | 2,150         | 11,760             | 1,510                       | 970           | 3,300         | 2,260         |
| Georgia              | 17,730         | 500                         | 1,320            | 1,580             | 620           | 890           | 4,650              | 530                         | 420           | 1,210         | 870           |
| Hawaii               | 2,580          | 50                          | 160              | 230               | 90            | 180           | 590                | 100                         | †             | 230           | 120           |
| Idaho                | 3,020          | 100                         | 210              | 240               | 120           | 140           | 680                | 110                         | 80            | 240           | 200           |
| Illinois             | 24,670         | 620                         | 1,720            | 2,080             | 980           | 1,100         | 6,410              | 790                         | 560           | 1,680         | 1,160         |
| Indiana              | 13,820         | 350                         | 860              | 1,110             | 550           | 550           | 3,960              | 450                         | 290           | 910           | 600           |
| Iowa                 | 6,570          | 190                         | 370              | 570               | 250           | 260           | 1,740              | 250                         | 150           | 460           | 300           |
| Kansas               | 5,600          | 170                         | 350              | 470               | 260           | 240           | 1,490              | 180                         | 120           | 420           | 260           |
| Kentucky             | 10,590         | 260                         | 580              | 830               | 380           | 440           | 3,530              | 320                         | 190           | 660           | 390           |
| Louisiana            | 9,370          | 220                         | 610              | 830               | 330           | 550           | 2,580              | 290                         | 170           | 730           | 400           |
| Maine                | 3,360          | 100                         | 180              | 230               | 130           | 120           | 970                | 110                         | 60            | 230           | 150           |
| Maryland             | 10,780         | 290                         | 810              | 870               | 420           | 580           | 2,560              | 340                         | 260           | 850           | 530           |
| Massachusetts        | 12,610         | 370                         | 750              | 890               | 520           | 650           | 3,180              | 380                         | 320           | 960           | 600           |
| Michigan             | 21,380         | 570                         | 1,400            | 1,670             | 840           | 880           | 5,860              | 750                         | 500           | 1,610         | 940           |
| Minnesota            | 10,080         | 300                         | 630              | 770               | 460           | 410           | 2,420              | 380                         | 230           | 750           | 520           |
| Mississippi          | 6,750          | 220                         | 420              | 640               | 230           | 310           | 1,930              | 170                         | 110           | 490           | 310           |
| Missouri             | 13,280         | 320                         | 850              | 1,050             | 520           | 580           | 3,950              | 370                         | 250           | 920           | 550           |
| Montana              | 2,110          | 70                          | 140              | 180               | 80            | 90            | 510                | 70                          | 50            | 150           | 130           |
| Nebraska             | 3,550          | 110                         | 230              | 320               | 150           | 130           | 890                | 130                         | 70            | 250           | 190           |
| Nevada               | 5,330          | 150                         | 390              | 520               | 210           | 240           | 1,380              | 150                         | 120           | 380           | 280           |
| New Hampshire        | 2,810          | 80                          | 170              | 190               | 110           | 100           | 760                | 80                          | 70            | 210           | 130           |
| New Jersey           | 16,040         | 430                         | 1,250            | 1,400             | 650           | 720           | 3,670              | 510                         | 400           | 1,300         | 750           |
| New Mexico           | 3,750          | 100                         | 260              | 340               | 140           | 240           | 760                | 120                         | 110           | 270           | 220           |
| New York             | 35,350         | 900                         | 2,390            | 2,970             | 1,460         | 1,710         | 8,490              | 1,200                       | 910           | 2,760         | 1,680         |
| North Carolina       | 20,380         | 540                         | 1,370            | 1,570             | 760           | 1,010         | 5,770              | 610                         | 430           | 1,390         | 940           |
| North Dakota         | 1,290          | †                           | 80               | 110               | 60            | †             | 310                | 50                          | †             | 90            | 70            |
| Ohio                 | 25,740         | 640                         | 1,700            | 2,100             | 1,000         | 1,040         | 7,200              | 860                         | 550           | 1,860         | 1,110         |
| Oklahoma             | 8,470          | 210                         | 530              | 750               | 350           | 400           | 2,460              | 270                         | 190           | 540           | 390           |
| Oregon               | 8,310          | 260                         | 530              | 650               | 310           | 480           | 2,000              | 280                         | 240           | 620           | 450           |
| Pennsylvania         | 28,620         | 710                         | 1,880            | 2,380             | 1,180         | 1,270         | 7,280              | 970                         | 670           | 2,160         | 1,300         |
| Rhode Island         | 2,180          | 50                          | 130              | 160               | 90            | 120           | 610                | 60                          | 50            | 150           | 100           |
| South Carolina       | 10,630         | 270                         | 710              | 860               | 400           | 470           | 2,900              | 300                         | 230           | 730           | 520           |
| South Dakota         | 1,680          | 60                          | 110              | 160               | 80            | 60            | 440                | 50                          | †             | 110           | 80            |
| Tennessee            | 14,900         | 350                         | 920              | 1,220             | 540           | 700           | 4,480              | 460                         | 310           | 960           | 600           |
| Texas                | 41,030         | 1,130                       | 2,880            | 3,740             | 1,660         | 2,700         | 9,310              | 1,330                       | 920           | 2,880         | 1,830         |
| Utah                 | 3,270          | 130                         | 280              | 280               | 170           | 150           | 470                | 130                         | 110           | 270           | 220           |
| Vermont              | 1,450          | 50                          | 80               | 110               | 50            | 50            | 390                | 50                          | †             | 110           | 60            |
| Virginia             | 15,260         | 400                         | 1,090            | 1,210             | 550           | 720           | 3,780              | 490                         | 370           | 1,120         | 700           |
| Washington           | 13,030         | 400                         | 860              | 970               | 520           | 710           | 3,080              | 450                         | 340           | 950           | 690           |
| West Virginia        | 4,900          | 110                         | 280              | 430               | 200           | 190           | 1,470              | 150                         | 90            | 300           | 180           |
| Wisconsin            | 11,840         | 360                         | 720              | 890               | 520           | 450           | 3,000              | 420                         | 230           | 890           | 620           |
| Wyoming              | 980            | †                           | 70               | 80                | 60            | †             | 220                | †                           | †             | 70            | †             |
| <b>United States</b> | <b>609,640</b> | <b>16,830</b>               | <b>40,920</b>    | <b>50,630</b>     | <b>24,370</b> | <b>30,200</b> | <b>154,050</b>     | <b>19,910</b>               | <b>14,070</b> | <b>44,330</b> | <b>29,430</b> |

\*Rounded to the nearest 10. †Estimate is fewer than 50 deaths. ‡Liver includes intrahepatic bile duct. These estimates are offered as a rough guide and should be interpreted with caution. State estimates may not sum to US total due to rounding and exclusion of state estimates fewer than 50 deaths.

**Please note:** Estimated deaths for additional cancer sites by state can be found in Supplemental Data at [cancer.org/statistics](http://cancer.org/statistics) or via the Cancer Statistics Center at [cancerstatisticscenter.cancer.org](http://cancerstatisticscenter.cancer.org).



**Statement from President Donald J. Trump  
on  
National Prostate Cancer Awareness Month  
September 1, 2017**

During National Prostate Cancer Awareness Month, I join my fellow Americans in supporting those who battle prostate cancer and reaffirm our Nation's commitment to making this a world free from cancer.

We have good reason to be hopeful about overcoming prostate cancer. The rate of new prostate cancer cases in the United States has fallen nearly 6 percent on average each year over the past decade. During this same time, the rate of deaths due to prostate cancer has also fallen by more than 3 percent on average each year. Men diagnosed with prostate cancer are living longer lives than ever thanks to innovative research and improvements in cancer treatment. Our Nation applauds these ongoing efforts to enhance the lives of Americans and provide comfort and support in the fight against cancer.

Nonetheless, in fighting prostate cancer, we are still mindful that it remains the second leading cause of cancer deaths among men. My Administration remains dedicated to finding better diagnostic and treatment options through the 21st Century Cures Act, as well as research collaborations between the Department of Health and Human Services, private industry, and the academic community. In addition, the National Institutes of Health is investing in research that will improve upon current approaches to combatting prostate cancer. Through these efforts and others, American men can experience a healthier future.

This month, I encourage men to talk with their healthcare providers about their risk for prostate cancer. I also call upon all Americans to do their part in raising awareness of this disease. We pray for Americans currently fighting prostate cancer and recognize the progress yet to be made in finding its cure.

Ref: <https://www.whitehouse.gov/the-press-office/2017/09/01/statement-president-donald-j-trump-national-prostate-cancer-awareness>

File: Whitehouse, 09-01-17, wd



115th CONGRESS – 1st Session

**S. RES. 269**

**Designating September 2017 as National Prostate Cancer Awareness Month  
IN THE SENATE OF THE UNITED STATES**

September 27, 2017

**RESOLUTION**

Mr. Schumer (for Mr. Menendez (for himself, Mr. Crapo, Mr. Markey, Mrs. Feinstein, Mr. Cardin, Mr. Booker, Mr. Blunt, and Mr. Coons)) submitted the following resolution; which was considered and agreed

Whereas over 2,900,000 families in the United States live with prostate cancer;

Whereas 1 in 7 men in the United States will be diagnosed with prostate cancer in their lifetimes;

Whereas prostate cancer is the most commonly diagnosed nonskin cancer and the third-leading cause of cancer-related deaths among men in the United States;

Whereas the American Cancer Society estimates that in 2017, 161,360 men will be diagnosed with, and more than 26,730 men will die of, prostate cancer;

Whereas 43 percent of newly diagnosed prostate cancer cases occur in men under the age of 65;

Whereas the odds of developing prostate cancer rise rapidly after age 50;

Whereas African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have double the prostate cancer mortality rate than that of White men;

Whereas having a father or brother with prostate cancer more than doubles the risk of a man developing prostate cancer, with a higher risk for men who have a brother with the disease and the highest risk for men with several affected relatives;

Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent;

Whereas only 29 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized;

Whereas there are no noticeable symptoms of prostate cancer in the early stages, making appropriate screening critical;

Whereas, in fiscal year 2017, the Director of the National Institutes of Health supported approximately \$274,000,000 in research projects focused specifically on prostate cancer;

Whereas ongoing research promises further improvements in prostate cancer prevention, early detection, and treatment; and

Whereas educating people in the United States, including health care providers, about prostate cancer and early detection strategies is crucial to saving the lives of men and preserving and protecting families: Now, therefore, be it

That the Senate—

(1)  
designates September 2017 as National Prostate Cancer Awareness Month;

(2)  
declares that steps should be taken—

(A)  
to raise awareness about the importance of screening methods for, and treatment of, prostate cancer;

(B)  
to encourage research—

(i)  
to improve screening and treatment for prostate cancer;

(ii)  
to discover the causes of prostate cancer; and

(iii)  
to develop a cure for prostate cancer; and

(C)  
to continue to consider ways to improve access to, and the quality of, health care services for detecting and treating prostate cancer; and

(3)  
calls on the people of the United States, interest groups, and affected persons—

(A)  
to promote awareness of prostate cancer;

(B)  
to take an active role in the fight to end the devastating effects of prostate cancer on individuals, families, and the economy; and

(C)  
to observe National Prostate Cancer Awareness Month with appropriate ceremonies and activities.



**California Senate Concurrent Resolution Number 27  
Prostate Cancer Awareness Month  
September 2017**

**Introduced by Senator Gaines, February 23, 2017**

**SCR 27 designates  
September 2017 as Prostate Cancer Awareness Month in the State of California.**

**WHEREAS**, Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. An estimated one in eight men will develop this disease in his lifetime; and

**WHEREAS**, The American Cancer Society estimates that there will be 161,360 new cases of prostate cancer in the United States in 2017, resulting in an estimated 26,730 deaths; and

**WHEREAS**, An estimated 14,520 men in California will be diagnosed with prostate cancer this year, and an estimated 3,130 men in California will die from this disease; and

**WHEREAS**, Men of African American descent have the highest prostate cancer incidence rates in the world, and their prostate cancer mortality rate in the United States is more than twice that of any other ethnic group of men; and

**WHEREAS**, Early prostate cancer usually has no symptoms, and studies suggest strong familial predisposition may be responsible for 5 percent to 10 percent of the disease cases; and

**WHEREAS**, Advanced prostate cancer commonly spreads to the bones, which can cause pain in the hips, spine, ribs, or other areas in the body; and

**WHEREAS**, The five-year survival rate approaches 100 percent when prostate cancer is diagnosed and treated early, but it drops to 29 percent when it spreads to other parts of the body; and

**WHEREAS**, Treatment options for prostate cancer vary depending on a man's age, the stage and grade of his cancer, and his other existing medical conditions; and

**WHEREAS**, The American Cancer Society recommends that a man should have an opportunity to make an informed decision about whether to be tested for prostate cancer based on his personal values and preferences; now, therefore, be it

**Resolved** by the Senate of the State of California, the Assembly thereof concurring, That the Legislature hereby proclaims the month of September 2017 as Prostate Cancer Awareness Month in California; and be it further

**Resolved**, That the Legislature joins communities across our nation to increase awareness about the importance for men to make informed decisions with their health care providers about early detection and testing for prostate cancer; and be it further

**Resolved**, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.

• • •